Background {#Sec1}
==========

Anti-glomerular basement-membrane (anti-GBM) disease is an autoimmune disorder that is characterized by pulmonary hemorrhage and rapidly progressive glomerulonephritis, which usually manifests as acute renal failure. It is termed Goodpasture disease when both manifestations are simultaneously exhibited. This rare disease occurs in 1 person per million /year and generally evolves as a single acute phase, it relapses rarely \[[@CR1]\]. Anti-GBM disease is caused by antibodies against non-collagenous domain-1 of the alpha-3 and alpha-5 chain in type IV collagen. The diagnosis is made by detecting circulating anti-GBM antibodies and a kidney biopsy provides a definitive diagnosis when there is renal involvement. Using light microscopy, focal proliferative or necrotizing crescentic glomerulonephritis is observed. The pathognomonic finding is linear deposition of immunoglobulin G (IgG) along the glomerular basement membrane seen by direct immunofluorescence \[[@CR2]\].

Before the advent of plasmapheresis therapy, the mortality rate was \~ 90%. Today, patient survival at 1 year is 100% when creatinine level is \< 5.6 mg/dL at presentation \[[@CR3]\]. Reliable predictors for an adverse outcome include a serum-creatinine level of \> 6.8 mg/dL, dialysis-dependence, and a percentage of crescentic glomeruli of \> 50% at diagnosis \[[@CR2]--[@CR4]\]. The 2012 guidelines for Kidney Disease Improving Global Outcomes recommend initiating immunosuppression with cyclophosphamide plus corticosteroids and plasma exchange in all patients with anti-GBM glomerulonephritis, except for those that are dialysis-dependent at presentation and have 100% crescents on a biopsy and do not have a pulmonary hemorrhage \[[@CR5]\]. However, this approach results in a significant proportion of patients remaining dialysis-dependent plus causing significant side-effects.

Anti-GBM antibodies can be pathogenic and their removal is associated with renal recovery \[[@CR6]\]. The inhibition of their production through B-cell depletion could be of value. In renal vasculitis, e.g., ANCA-associated vasculitis, the use of the anti-CD20 monoclonal antibody, rituximab, has been reported to be efficacious in large randomized controlled studies \[[@CR7], [@CR8]\]. Herein, we report on the largest series of patients with Goodpasture syndrome, where the first-line immunosuppressive therapy was based on rituximab.

Methods {#Sec2}
=======

We retrospectively reviewed the medical files of all patients with anti-GBM disease in our hospital between January 2013 to December 2016. Only five patients (1 male and 4 females) aged 18 to 75 years were treated during this period with Rituximab as first line therapy. Patients gave their verbal informed consent. Our local ethics committee (CPP Grenoble) ruled that no formal ethics approval is required in this particular case, i.e. routine patients 'care. The patients' characteristics are summarized in Table [1](#Tab1){ref-type="table"}. At diagnosis, all five patients had serious clinical presentations with a median creatinine value of **\>** 6.8 mg/dL (0.5--9). Four patients required dialysis within 7 days after diagnosis. Three patients (patient nos. 2, 3, 5) had an intra-alveolar hemorrhage and one of them (no. 3) required assisted ventilation. All patients were positive for anti-GBM antibodies. Two patients were double-positive with ANCA. Table [2](#Tab2){ref-type="table"} shows the clinical findings. A kidney biopsy was performed at diagnosis in three of the four patients that had renal impairment; the fourth patient declined a biopsy. Patients 2 and 5 had \> 90% crescentic glomeruli; patient 1 had only 20%. Linear IgG staining without IgA was demonstrated on the glomerular basement membrane of all biopsies. Patient 3 did not have renal involvement. One patient was young (18-years-old) and rituximab was chosen because of the risk of infertility; the other patients had very poor renal prognosis, i.e. all were dialysis-dependent at diagnosis and cyclophosphamide has not demonstrated in this situation efficacy in helping recovery of kidney function. Finally, as these patients were old we thought that they were at high risk for cyclophosphamide-induced infectious complication. All patients received the same induction therapy with rituximab administered as four weekly pulses of 375 mg/m^2^ associated with daily plasma exchange (6 days/week) until the antibodies became undetectable (the replacement liquid was albumin, fresh-frozen plasma, or a combination). Pulses of methylprednisolone were given, followed by prednisone, which was gradually tapered. No patient received cyclophosphamide.Table 1Characteristics of the five patientsAt diagnosisAge (median, ranges)72 (17 to 96)Gender (M/F)1/4Comorbidities Hypertension2/5 Tobacco2/5 Diabetes mellitus0/5 Toxic exposure0/5Pulmonary symptoms3/5Mechanical ventilation required1/5Serum creatinine μmol/L (median, ranges)605 (47 to 800)Dialysis required at diagnosis4/5Proteinuria g/L (median, ranges)4 (0.2 to 6)Biological characteristics Hemoglobin g/L (mean, ranges)95 (76 to 116) Anti-GBM titer of dilution (IIF) (mean, ranges)97 (5 to 640) ANCA +2/5Crescents \> 50% on biopsy2/3Treatment Number of plasma-exchange sessions, mean (range)16 (9 to 23) Corticosteroids5/5 Rituximab as a first-line treatment5/5*Abbreviations: F* female, *M* male, *IIF* indirect immunofluorescence, *ANCA* anti-neutrophil-cytoplasmic antibody, *anti-GBM* anti glomerular-basement-membraneTable 2Patients characteristics and treatment summaryPatientInitial clinical presentationCreatinine at diagnosisIinitial dialysisCrescentsInitialANCANumber of plasma exchange sessionsCorticosteroidsRituximabOutcomeComplicationsFollow up durationEvolution(μmol/L)within 7 days after diagnosison biopsyanti-GBM titer (IIF)(months)Patient 1general weakness, AKI706yes20%1/10negative9120 mg ×3  + 1 mg/kg375 mg/m2 ×4ESRDno39TransplantationPatient 2AKI with diarrhea, dyspnea and desaturation, alveolar hemorrhage800yes90%1/80positive, MPO231 mg/Kg375 mg/m2 ×4Pulmonary recovery, ESRDno23HemodialysisPatient 3hemoptysis, respiratory distress with mechanical ventilation, AKI in intensive care47noNA1/5positive, non specific101 mg/kg375 mg/m2 ×4Pulmonary recoverycandida colonization4Creatinine 48 μmol/LPatient 4rapidly progressing glomerulonephritis, hematuria273yesNA1/640negative21500 mg × 4 + 1 mg/kg375 mg/m2 ×4ESRDEsophageal candidiasis + temporary9Peritoneal dialysisthrombocytopeniaPatient 5hemoptysis,AKI605yes100%1/200negative20500 mg × 3+ 1 mg/kg375 mg/m2 ×4Pulmonary recovery, ESRDno14Transplantation*Abbreviations*: *ESRD* end stage renal disease, *F* female, *M* male, *AKI* acute kidney injury, *IIF* indirect immunofluorescence, *ANCA* anti-neutrophile-cytoplasm antibody, *anti-GBM* anti glomerular-basement-membrane antibody, *NA* data not available

All patients recovered rapidly from the lung injury, even the patient that required mechanical ventilation (no. 3). However, there was no renal recovery within a median follow-up of 14 months (range 4--39) in the four patients that were dialysis-dependent at presentation. Antibodies became undetectable in all five patients by a median of 19 days (range 2--26) after the first plasma exchange and by a median of 19 days (range 5--30) after the first perfusion of rituximab. Antibodies then remained undetectable during the follow-up period. One infectious and two hematologic (initial thrombocytopenia, leucopenia at 6 months) complications, within the same patient, were observed. During the follow-up, two patients received a kidney allograft. No death or relapse occurred in any of the five patients.

Discussion {#Sec3}
==========

We report the outcomes of five patients that had Goodpasture disease and whose initial induction treatment was based on rituximab (instead of cyclophosphamide), plus prednisone and plasma exchange. Although pulmonary injury was reduced and the biological responses were good with no relapses, the renal outcomes were not improved.

Anti-GBM antibody-mediated disease is a fulminant disorder that has a poor prognosis and a mortality rate of up to 90% without treatment. However, despite intensive treatment, many patients (60%) remain dialysis-dependent \[[@CR4]\] and have adverse complications from immunosuppressive treatments \[[@CR3]\]. Since the discovery of a direct pathogenic effect of anti-GBM antibodies, therapies have aimed to decrease the production or increase the clearance of these antibodies. Thus, rituximab, an anti-CD20 monoclonal antibody, could be a good alternative to cyclophosphamide.

In the literature, the first use of rituximab for anti-GBM disease was reported in 2002 by Arzoo et al. for a patient with a pulmonary hemorrhage and that was refractory to conventional treatments \[[@CR9]\] (Table [3](#Tab3){ref-type="table"}A). Since this case, several small studies have been published, which suggest a good pulmonary response and good overall survival of patients, although renal outcomes were not significantly modified \[[@CR10]--[@CR12]\].Table 3Case series when using rituximab therapy in the setting of Goopasture syndrome as a second-line (A) or first-line (B) therapyArticleGenderAgeClinical findingsRenal injuryPulmonary symptomsCreatinine μmol/L (GFR ml/min/1.73m^2^)Anti-MBG at diagnosis or at initiation of rituximabPrevious treatmentRituximab indicationTreatment associated with rituximabRituximabRenal outcomePulmonary symptomAnti-MBG U/mlA. RITUXIMAB AS A SECOND-LINE THERAPYArzoo et al.F73hypoxia, haemoptysis, mechanical ventilation, haematurianoyesND51(ELISA)CYC,PE, CTCrelapse at one year, 2nd treatment failureCYC PO, corticosteroids6 times weekly 375 mg/m^2^recoverynoundetectableShah et al.M54severe renal failure, anuria, hypertensionyesyes1874 (dialysis dependent)680 (U/ml)CYC IV (500 mg) one dose, PE = 50, corticosteroidshaematological complication of CYC after one dose (on day 5)PE = 50, corticosteroids4 times weekly 375 mg/m^2^dialysis dependentnoundetectableM64nasal obstruction, nausea, weight loss, AKIyesND536 (dialysis dependent)49 (ELISA)CYC PO (50 mg/d) for 7 days, PE, corticosteroidshaematological complication of CYC after 7 daysPE, corticosteroids4 times weekly 375 mg/m^2^dialysis independent after 4th rituximab, creatinine 260 μmol/LNDundetectableSyeda et al.F68renal failure, TTPyesno994(dialysis dependent)1/160 (IIF)CYC (2 mg/kg/d) for 5 days, PE, corticosteroidshaematological complication of CYC after 5 daysPE, corticosteroidsD28, 4 times weekly 375 mg/m^2^dialysis dependentnoundetectableTouzot et al.F21renal failure, pulmonary haemorrhageyesyesGFR 270 (ELISA)CYC IV (1000 mg) PE = 13, corticosteroidsseverity of diseasecorticosteroids4 times weekly 375 mg/m^2^GFR 35noundetectableF46renal failureyesnodialysis dependent1/200 (IIF)CYC IV (1000 mg) PE = 15, corticosteroidsseverity of disease, PE dependencycorticosteroids4 times weekly 375 mg/m^2^dialysis dependentnoundetectableF16renal failure, haemodynamic instabilityyesnoGFR 1050 (ELISA)CYC IV (2000 mg) PE = 1,1 corticosteroidsseverity of disease (ECMO)corticosteroids, MMF 720 mg/d4 times weekly 375 mg/m^2^GFR 103noundetectableM65NDyesNDGFR 171/40 (IIF)CYC IV (2000 mg) PE = 9, corticosteroidspersistent anti-GBM antibodiescorticosteroids, MMF 720 mg/d4 weekly 375 mg/m2GFR 25noundetectableF19NDyesNDGFR 2925(ELISA)CYC IV (1400 mg) PE = 25, corticosteroidsPE dependencyCYC IV (500 mg) PE = 10 corticosteroids4 times weekly 375 mg/m^2^GFR 96noundetectableM22NDnoyesGFR 12619(ELISA)CYC IV (4500 mg) PE = 0, corticosteroidsrelapse at 3 years, alternative therapycorticosteroids4 times weekly 375 mg/m^2^GFR 108noundetectableF17NDyesyesGFR 538 (ELISA)CYC IV (3000 mg),PE = 0, CorticosteroidsRelapse at 6 months after decrease of corticosteroidsPE = 6,CYC = 60 0 mg ×3, Prednisone4 times weekly 375 mg/m^2^Dialysis dependentnoundetectableF21NDyesnoGFR 4640(ELISA)CYC IV (900 mg) PE = 0, corticosteroidsseverity of diseaseCYC IV (900 mg) PE = 19 corticosteroids4 times weekly 375 mg/m^2^GFR 74noundetectableSauter et al.M29renal failure, pulmonary haemorrhageyesyes14043CYC, PE =17, corticosteroidsrelapse at 18 months after transplantationPE, MMF 3000 mg/d then replaced by CYC PO, corticosteroids3 weekly 375 mg/m2dialysis dependent, graft lostnoundetectableBandak et al.M24Haemoptysis haematuria, AKIyesno379161CYC PO (150 mg/d) 6 months, PE = 17, corticosteroidstreatment failureCYC+ corticosteroidsone dose, 1000 mgcreatinine 181 μmol/LnoundetectableB. RITUXIMAB USED AS A FIRST-LINE THERAPYWechsler et al.M55Haematuria, AKI in HIV, diabetic patient with septic hip arthritisyesno3108,6noinfectious riskMMF 1000 mgx2/d, corticosteroids IgIV4 times weekly 375 mg/m^2^creatinine 106 μmol/LnoundetectableShah et al.M17nausea, weakness, haemoptysis, weight lossyesyes272131nofertilityPE = 17, corticosteroids2 times weekly 375 mg/m^2^creatinine 99 μmol/LnoundetectableNarayanan et al.M21Oliguria, weakness, oedema, haemoptysisyesyes1126191nofertilityPE = 5, corticosteroids2 doses, two weeks apartdialysis dependentnoundetectable*Abbreviations: ESRD* end-stage renal disease, *F* female, *M* male, *AKI* acute kidney injury, *IIF* indirect immunofluorescence, *ANCA* anti-neutrophil-cytoplasm antibody, *anti-GBM* anti-glomerular basement membrane antibody, *MMF* mycophenolate mofetil, *PE* plasma exchange, *GFR* glomerular-filtration rate, *CYC* cyclophosphamide, *IgIV* immunoglobulin intravenous, *PO* per os, IV intravenous, *ECMO* extracorporeal membrane oxygenation

Currently, an initial induction treatment with rituximab, instead of cyclophosphamide, has been described in only three case reports (Table [3](#Tab3){ref-type="table"}B). Wechsler et al. reported on a case with renal involvement (baseline plasma creatinine: 3.5 mg/dL, tubular-cell necrosis, and only one crescent on a biopsy) but no pulmonary symptoms. The patient had an HIV infection (human immunodeficiency virus), mellitus diabetes, and septic hip arthritis. He was treated with rituximab combined with prednisone, IV immunoglobulin, and mycophenolate mofetil to avoid infection. Evolution was good: at one month after initiation of therapy, renal function was improved (creatinine 1.1 mg/dL and antibodies were undetectable). This patient presented with only one complication, *Candida* esophagitis. In this case, a poor prognosis was not identified at diagnosis**,** thus, it is possible that the resolution of tubular-cell necrosis contributed to the renal recovery \[[@CR13]\].

The second case report, by Shah et al., was on an 18-year-old patient that was treated with plasma exchange, prednisone, plus rituximab to preserve fertility because of his young age. He presented with major pulmonary injury and moderate renal impairment (80% of glomeruli were involved as shown by cellular crescents in a kidney biopsy and baseline plasma-creatinine of 3 mg/dL). Antibodies became undetectable at 20 days after initiating rituximab. No complications were reported and, after a follow-up of 33 months, he had renal (plasma creatinine of 1.1 mg/dL) and pulmonary recovery \[[@CR14]\].

The third case report, reported by Narayanan et al., describes a young man with pulmonary and acute kidney injury that required dialysis (creatinine at diagnosis 12.8 mg/dL and 100% crescents in a kidney biopsy). He received plasma exchanges, corticosteroids and rituximab. After 4 months of follow-up, he had completely recovered from the pulmonary hemorrhage, the antibodies had become undetectable, but he remained dialysis dependent \[[@CR15]\].

Only 16 other cases have been reported on anti-GBM disease treated with rituximab as a second-line therapy \[[@CR9], [@CR11], [@CR13]--[@CR16]\] (see Table [3](#Tab3){ref-type="table"}A). In most cases, the treatment strategies were heterogeneous and cyclophosphamide was used as the first-line therapy. Rituximab was initiated primarily as a rescue therapy because the initial conventional treatment had failed or there were serious adverse events. Among these published cases, four patients had very poor renal prognoses (creatinine \> 6.8 mg/dL or were dialyzed at presentation) of whom three remained dialysis-dependent despite treatment \[[@CR10], [@CR11], [@CR14]\]. Among 12 patients that were not dialysis-dependent at baseline, two patients did not recover renal function and progressed to end-stage renal disease \[[@CR10], [@CR12]\]. Pulmonary symptoms were identified in six patients and all recovered \[[@CR9], [@CR10], [@CR12], [@CR14]\]. Among the 16 patients, rituximab was administered for a disease relapse that was limited to the lungs in two patients; these relapses occurred at 1 and 3 years after the initial therapy. These two patients were successfully treated and had no complications \[[@CR9], [@CR10]\]. Renal relapse developed in two other patients, this occurred at 6 months after the initial treatment, with cortico-dependency \[[@CR10]\], in one case and at 36 months after transplantation \[[@CR12]\] in the second case. Both these patients progressed to end-stage renal disease despite the use of rituximab.

Because anti-GBM antibodies are considered pathogenic their titers were monitored in most published studies. Cui et al. reported that anti-GBM antibodies remained positive for \~ 29 days with conventional treatment that combined plasma exchange, cyclophosphamide, and corticosteroids \[[@CR1]\]. In most cases, a good biological response to rituximab was reported but the number of plasma exchanges required varied from 10 to 50 sessions. Similar to these observations, we found a clearance in anti-GBM antibodies within a median time of 19 days (range 2--26) after rituximab infusion.

Anti-GBM removal is usually achieved after a median time of 19 days of plasma exchange, but immunoadsorption can also be efficacious. Bisenbach et al., in 2014, described ten patients treated with immunoadsorption plus prednisone and cyclophosphamide. This protocol enabled rapid removal of anti-GBM antibodies (undetectable within 2--9 immunoadsorption sessions, i.e. \< 1 month) and led to rapid clinical remediation of the pulmonary hemorrhage and improved renal function. Three of six patients that were dialysis-dependent remained free of dialysis for 64, 23, and 9 months. To our knowledge, there are no data on the efficacy and safety of immunoadsorption combined with rituximab to treat anti-GBM disease \[[@CR17]\].

The cases reported in the literature have several limitations. The indications, the times to initiation of rituximab treatment, durations of treatment and total doses of rituximab, and the range of combined treatment strategies varied between patients. However, the reported outcomes uniformly suggest a good pulmonary response although renal outcomes were not significantly modified. The survival of patients was excellent and almost no complications occurred. This agrees with our findings.

The strength of our study is that all of our patients received homogeneous similar treatments. However, the retrospective nature of our study, the limited number of patients, and the lack of a comparator control group with another strategy to deplete anti-GBM antibodies, prohibits us from forming strong conclusions. Our patients had poor prognostic indicators at presentation, including high plasma creatinine and high percentages of cellular crescents on kidney biopsies.

Conclusions {#Sec4}
===========

This is the first report to include five patients that received rituximab as part of a first-line induction therapy for anti-GBM disease. Our findings suggest that rituximab effectively induced complete resolution of pulmonary hemorrhage. It was associated with a good biological response with no major life-threatening adverse events. However, renal outcome was not significantly improved for patients that were dialysis-dependent at presentation. Whether other strategies that combine B-cell depletion and the removal of antibodies with immunoadsorption can be more effective and needs investigation.
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